Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Size & Outlook
Middle East & Africa non-alcoholic steatohepatitis biomarkers market, 2018-2030 (US$M)
Related Markets
MEA non-alcoholic steatohepatitis biomarkers market highlights
- The MEA non-alcoholic steatohepatitis biomarkers market generated a revenue of USD 18.5 million in 2021.
- The market is expected to grow at a CAGR of 20.5% from 2022 to 2030.
- In terms of segment, serum biomarkers was the largest revenue generating type in 2021.
- Hepatic Fibrosis Biomarkers is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2022 to 2030.
MEA data book summary
| Market revenue in 2021 | USD 18.5 million |
| Market revenue in 2030 | USD 99.1 million |
| Growth rate | 20.5% (CAGR from 2021 to 2030) |
| Largest segment | Serum biomarkers |
| Fastest growing segment | Hepatic Fibrosis Biomarkers |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
| Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.2% of the global non-alcoholic steatohepatitis biomarkers market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 925.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non-alcoholic Steatohepatitis Biomarkers Market Scope
Non-alcoholic Steatohepatitis Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa non-alcoholic steatohepatitis biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.97% in 2021. Horizon Databook has segmented the Middle East & Africa non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
Rising demand for biomarkers in this region is one of the major factors expected to contribute to the market growth. Growing need for improved healthcare infrastructure and high burden of various diseases, such as diabetes & obesity, are expected to increase the prevalence of NASH and demand for biomarkers. Growing economic development, coupled with high unmet healthcare needs, is fueling market growth.
Reasons to subscribe to Middle East & Africa non-alcoholic steatohepatitis biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa non-alcoholic steatohepatitis biomarkers market databook
-
Our clientele includes a mix of non-alcoholic steatohepatitis biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA non-alcoholic steatohepatitis biomarkers market size, by country, 2018-2030 (US$M)
Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
